AFT’s core Australian business under-appreciated, analysts say
Forsyth Barr rates the Kiwi pharma as an outperform stock.
AFT Pharmaceuticals CEO Dr Hartley Atkinson.
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
The market has underappreciated Kiwi drug manufacturer AFT Pharmaceuticals’s core Australia business, says Forsyth Barr in a glowing note after expanding its coverage of the stock.
The NZX and ASX-listed company’s share price has been languishing this year, down 20% on a year ago but Forsyth
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
